Evaluating and treating cardiometabolic risk factors: a case discussion.
Reducing the risk for coronary heart disease (CHD) requires a comprehensive assessment of cardiometabolic risk factors along with the initiation of nonpharmacologic and pharmacologic therapies to mitigate these risk factors. A case study is presented to illustrate the approach to evaluating a patient and selecting among available and emerging therapeutic modalities to reduce CHD risk.
Haines
Stuart T
ST
School of Pharmacy, Division of Endocrinology, Diabetes, and Nutrition, School of Medicine, University of Maryland, Baltimore, Maryland 21201-1082, USA. shaines@rx.umaryland.edu
Fuke
Dawn C
DC
Lender
Dan
D
Rodgers
Philip T
PT
Sysko
Suzanne K
SK
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D004032:Diet; D050171:Dyslipidemias / Q000188:drug therapy; D015444:Exercise; D005260:Female; D006331:Heart Diseases / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008875:Middle Aged; D009765:Obesity / Q000628:therapy; D012307:Risk Factors; D012907:Smoking; D016540:Smoking Cessation
D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D001241:Aspirin